Citation Impact
Citing Papers
Patterns of Cancer Incidence, Mortality, and Prevalence Across Five Continents: Defining Priorities to Reduce Cancer Disparities in Different Geographic Regions of the World
2006 Standout
Circulating microRNAs as stable blood-based markers for cancer detection
2008 Standout
Tumor imaging by means of proteolytic activation of cell-penetrating peptides
2004 StandoutNobel
KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)
2009 Standout
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
2012 Standout
FRAX™ and the assessment of fracture probability in men and women from the UK
2008 Standout
The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials
2001 Standout
Osteoporosis
2019 Standout
Testosterone Therapy in Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline
2010 Standout
The Profile of Soluble Amyloid β Protein in Cultured Cell Media
1996
Update on screening for prostate cancer with prostate-specific antigen
2004
Aβ Oligomers – a decade of discovery
2007 Standout
CSF biomarkers for mild cognitive impairment
2004
Cerebrospinal fluid A?42 is increased early in sporadic Alzheimer's disease and declines with disease progression
1999
Cerebrospinal fluid protein biomarkers for Alzheimer’s disease
2004
Nomograms in oncology: more than meets the eye
2015 Standout
Multiplexed electrical detection of cancer markers with nanowire sensor arrays
2005 Standout
Long Noncoding RNAs in Cancer Pathways
2016 Standout
Lifestyle-related factors and environmental agents causing cancer: An overview
2007 StandoutNobel
The neurobiology of zinc in health and disease
2005 Standout
Oxidative stress and the amyloid beta peptide in Alzheimer’s disease
2017 Standout
Analysis of Heterogeneous βA4 Peptides in Human Cerebrospinal Fluid and Blood by a Newly Developed Sensitive Western Blot Assay
1996
Oligosaccharide Profiles of the Prostate Specific Antigen in Free and Complexed Forms from the Prostate Cancer Patient Serum and in Seminal Plasma: a Glycopeptide Approach
2007
Dramatic Aggregation of Alzheimer Aβ by Cu(II) Is Induced by Conditions Representing Physiological Acidosis
1998
Carotenoids and human health
2007 Standout
Serum and Tissue Lycopene and Biomarkers of Oxidation in Prostate Cancer Patients: A Case-Control Study
1999
Bone Quality — The Material and Structural Basis of Bone Strength and Fragility
2006 Standout
High-throughput analysis of N-glycans using AutoTip via glycoprotein immobilization
2017
Osteoporosis: now and the future
2011 Standout
The case for early detection
2003 Nobel
Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study
2004
Is the paradigm shifting?
2003
Pathogenic theories and intrathecal analysis of the sporadic form of Alzheimer’s disease
2002
Mild cognitive impairment (MCI) in medical practice: a critical review of the concept and new diagnostic procedure. Report of the MCI Working Group of the European Consortium on Alzheimer's Disease
2006 Standout
NMR studies in aqueous solution fail to identify significant conformational differences between the monomeric forms of two Alzheimer peptides with widely different plaque‐competence, Aβ(1–40)ox and Aβ(1–42)ox
2001 StandoutNobel
Plasma and Cerebrospinal Fluid Levels of Amyloid β Proteins 1-40 and 1-42 in Alzheimer Disease
2000
Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards
2010
Combination of the different biological markers for increasing specificity of in vivo Alzheimer’s testing
1998
Increased telomerase activity and comprehensive lifestyle changes: a pilot study
2008 StandoutNobel
Cerebrospinal Fluid β-Amyloid(1-42) in Alzheimer Disease
1999
EAU Guidelines on Prostate Cancer
2007 Standout
Biochemical Markers of Bone Turnover in the Clinical Development of Drugs for Osteoporosis and Metastatic Bone Disease
2006
Chronic arthritis leads to disturbances in the bone collagen network
2010 StandoutNobel
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
2009 Standout
Alzheimer's disease
2006 Standout
Cancer treatment and survivorship statistics, 2012
2012 Standout
NCCN Task Force Report: Bone Health in Cancer Care
2009
Anti-Aβ Drug Screening Platform Using Human iPS Cell-Derived Neurons for the Treatment of Alzheimer's Disease
2011 StandoutNobel
The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free‐to‐total prostate‐specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies?
2010
One-step immunostrip test for the simultaneous detection of free and total prostate specific antigen in serum
2005
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
2010 Standout
Liquid chromatography/tandem mass spectrometry characterization of oxidized amyloid beta peptides as potential biomarkers of Alzheimer's disease
2006
Discordant total and free prostate-specific antigen (PSA) assays: does calibration with WHO reference materials diminish the problem?
2009
Soluble pool of A? amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease
1999 Standout
Tau protein isoforms, phosphorylation and role in neurodegenerative disorders11These authors contributed equally to this work.
2000 Standout
A Pragmatic Guide to Enrichment Strategies for Mass Spectrometry–Based Glycoproteomics
2020 StandoutNobel
PI-RADS Prostate Imaging – Reporting and Data System: 2015, Version 2
2015 Standout
The clinical use of bone resorption markers in patients with malignant bone disease
2002
Neurodegenerative diseases and oxidative stress
2004 Standout
The Human Plasma Proteome
2002 Standout
The Assessment of Fracture Risk
2010
Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover
2006
Cell surface glycoproteomic analysis of prostate cancer-derived PC-3 cells
2011 StandoutNobel
Cumulative Prostate Cancer Risk Assessment with the Aid of the Free-to-Total Prostate Specific Antigen Ratio
2003
Solution structures of micelle-bound amyloid β-(1-40) and β-(1-42) peptides of Alzheimer’s disease 1 1Edited by P. E. Wright
1999
Cancer as an evolutionary and ecological process
2006 Standout
Associations of lower urinary tract symptoms with prostate‐specific antigen levels, and screen‐detected localized and advanced prostate cancer: a case‐control study nested within the UK population‐based ProtecT (Prostate testing for cancer and Treatment) study
2008
Gold nanoparticles in biomedical applications: recent advances and perspectives
2011 Standout
Prostate-specific antigen
2000
Aberrant PSA glycosylation—a sweet predictor of prostate cancer
2013
Glycosylation in cancer: mechanisms and clinical implications
2015 Standout
Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them
2014 Standout
Enhancement of sensitivity using hybrid stimulus for the diagnosis of prostate cancer based on polydiacetylene (PDA) supramolecules
2010
EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent—Update 2013
2013 Standout
Femtomole Immunodetection of Synthetic and Endogenous Amyloid-β Oligomers and Its Application to Alzheimer's Disease Drug Candidate Screening
2003
Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement
2012 Standout
Considerations for Development of Surrogate Endpoints for Antifracture Efficacy of New Treatments in Osteoporosis: A Perspective
2008
Serpin Structure, Mechanism, and Function
2002 Standout
Identification of Osteopenic Women at High Risk of Fracture: The OFELY Study
2005
Between-Method Differences in Prostate-Specific Antigen Assays Affect Prostate Cancer Risk Prediction by Nomograms
2011
SERUM PROTEOMIC PROFILING CAN DISCRIMINATE PROSTATE CANCER FROM BENIGN PROSTATES IN MEN WITH TOTAL PROSTATE SPECIFIC ANTIGEN LEVELS BETWEEN 2.5 AND 15.0 NG/ML
2004
Change in Bone Turnover and Hip, Non-Spine, and Vertebral Fracture in Alendronate-Treated Women: The Fracture Intervention Trial
2004
Prognostic value of serum markers for prostate cancer
2005
Changes in Bone Density and Turnover Explain the Reductions in Incidence of Nonvertebral Fractures that Occur during Treatment with Antiresorptive Agents
2002
Benefits and Harms of Prostate-Specific Antigen Screening for Prostate Cancer: An Evidence Update for the U.S. Preventive Services Task Force
2008
Can Urinary PCA3 Supplement PSA in the Early Detection of Prostate Cancer?
2014
Practice parameter: Management of dementia (an evidence-based review) [RETIRED]
2001 Standout
The Combination of Human Glandular Kallikrein and Free Prostate-specific Antigen (PSA) Enhances Discrimination Between Prostate Cancer and Benign Prostatic Hyperplasia in Patients with Moderately Increased Total PSA
1999
Copper Homeostasis and Neurodegenerative Disorders (Alzheimer's, Prion, and Parkinson's Diseases and Amyotrophic Lateral Sclerosis)
2006 Standout
Relationship Between Changes in Biochemical Markers of Bone Turnover and BMD to Predict Vertebral Fracture Risk
2004
Prostate Specific Antigen Best Practice Statement: 2009 Update
2009
Biochemical Markers of Bone Metabolism and Prediction of Fracture in Elderly Women
2004
PCA3: A Molecular Urine Assay for Predicting Prostate Biopsy Outcome
2008
Pretreatment Levels of Bone Turnover and the Antifracture Efficacy of Alendronate: The Fracture Intervention Trial
2006
Screening for Prostate Cancer: An Update of the Evidence for the U.S. Preventive Services Task Force
2002
Changes in prostate gene expression in men undergoing an intensive nutrition and lifestyle intervention
2008
Heritability of Prostate-Specific Antigen and Relationship with Zonal Prostate Volumes in Aging Twins*
2000
NCCN Task Force Report: Bone Health in Cancer Care
2013
Inhibition of Prostate-Specific Antigen (PSA) by α1-Antichymotrypsin: Salt-Dependent Activation Mediated by a Conformational Change
2002
From Estrogen-Centric to Aging and Oxidative Stress: A Revised Perspective of the Pathogenesis of Osteoporosis
2010 Standout
Predictive Value of BMD for Hip and Other Fractures
2005
Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity
2006 Standout
Water-Soluble Conjugated Polymers for Imaging, Diagnosis, and Therapy
2012 Standout
Prostate Cancer Detection in Patients With Total Serum Prostate-Specific Antigen Levels of 4–10 ng/mL: Diagnostic Efficacy of Diffusion-Weighted Imaging, Dynamic Contrast-Enhanced MRI, and T2-Weighted Imaging
2011
Type I Collagen Racemization and Isomerization and the Risk of Fracture in Postmenopausal Women: The OFELY Prospective Study
2002
PROSPECTIVE EVALUATION OF PROSTATE CANCER DETECTED ON BIOPSIES 1, 2, 3 AND 4: WHEN SHOULD WE STOP?
2001
Nature’s hierarchical materials
2007 Standout
Prostate Cancer
2001
Diffusion-Weighted MRI in the Body: Applications and Challenges in Oncology
2007 Standout
Cancer de la prostate
2007
Works of Robert E. Parson being referenced
Use of the Percentage of Free Prostate-Specific Antigen to Enhance Differentiation of Prostate Cancer From Benign Prostatic Disease
1998
Assessment of Amyloid β Protein in Cerebrospinal Fluid as an Aid in the Diagnosis of Alzheimer's Disease
1996
Serum Bone Alkaline Phosphatase and Calcaneus Bone Density Predict Fractures: A Prospective Study
2000
Biological Variation of Prostate Specific Antigen Levels In Serum: An Evaluation of Day-to-Day Physiological Fluctuations in a Well-Defined Cohort of 24 Patients
1997
PREDICTION OF POST-RADICAL PROSTATECTOMY PATHOLOGICAL OUTCOME FOR STAGE T1c PROSTATE CANCER WITH PERCENT FREE PROSTATE SPECIFIC ANTIGEN: A PROSPECTIVE MULTICENTER CLINICAL TRIAL
1999